The clinical feasibility and safety of CAR-T cell therapy for patients with GBM has been demonstrated on three targets, interleukin-13 receptor alpha 2 (IL13-Rα2), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor variant III (EGFRvIII) (6–8). The gene discussed is IL13RA2; the disease is glioblastoma.